Saturday 17 October 2026 Export JANX’s income statement to Excel — free account

Janux Therapeutics, Inc.

Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024. In the quarter to June 2026, revenue grew 2,238.7%, EPS grew 36.4% and free cash flow grew 150.6%, each against the same quarter a year earlier.

16.49 0.83 −4.79%

Follow JANX

Alert me

Market cap: $1.1B
P/E: 0.0×
Fwd P/E: −7.8×
Dividend yield: —
F-score: 2/9
Altman Z: 11.61
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.56

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	1	6	—	—	—	1	1	—	—	—	—

Insider Ownership 8.11%

Capital & Financial Ratios $m

Market Cap 1,060.00

Revenue 24.00

Net Income (102.59)

Free Cash Flow (41.92)

Net Debt (970.91)

Current Ratio 16.35

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (7.79)

P/S ratio 43.24

P/B ratio 1.12

Past 5Y EPS Growth —

This Y EPS Growth 4.60%

Next Y EPS Growth (53.18%)

Next Y revenue growth 194.20%

Next 5Y EPS Growth (22.05%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 6.23%

10-year low 10-year high

P/B against its own 10 years 23.74%

10-year low 10-year high

EV/Sales against its own 10 years 4.22%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	344	1,025	967	971
Receivables	—	—	—	0
Inventory	—	—	—	—
Other	—	—	—	—
	349	1,034	976	983

	2023	2024	2025	Q'26
Payables	2	4	5	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	13	17	25	60

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	5.11%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	167.50%	43.95%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	4	10	—	—	—
’25	—	—	10	—	10
’24	1	9	0	0	11
’23	2	1	3	2	8
’22	2	2	2	3	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	12	—	—	—
’25	(17)	(24)	(13)	(29)	(82)
’24	(15)	(10)	(2)	(17)	(44)
’23	(14)	(15)	(12)	(10)	(51)
’22	(12)	(6)	(13)	(12)	(43)
’21	6	(6)	(6)	(10)	(17)
’20	(1)	(2)	(1)	(2)	(4)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(13)	12	—	—	—
’25	(17)	(24)	(13)	(29)	(83)
’24	(15)	(10)	(2)	(17)	(44)
’23	(14)	(16)	(12)	(10)	(52)
’22	(12)	(7)	(16)	(14)	(49)
’21	5	(6)	(6)	(12)	(18)
’20	(1)	(2)	(1)	(2)	(4)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.39)	(0.35)	—	—	—
’25	(0.38)	(0.55)	(0.39)	(0.51)	(1.83)
’24	(0.30)	(0.11)	(0.51)	(0.36)	(1.28)
’23	(0.42)	(0.42)	(0.25)	(0.25)	(1.32)
’22	(0.32)	(0.41)	(0.40)	(0.39)	(1.52)
’21	(2.06)	(0.62)	(0.26)	(0.33)	(1.39)
’20	(0.03)	(2.76)	(1.33)	—	(7.41)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	14.39	9.39	5.65	7.79	13.62	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	37.99	20.85	23.64	71.71	61.59
People
People	Employees	—	—	—	—	16	33	60	64	81	109
	Revenue/emp, $m	—	—	—	—	0.00	0.11	0.14	0.13	0.13	0.09
Income, $m
Income, $m	Revenue	—	—	—	—	—	4	9	8	11	10
	Gross margin, %	—	—	—	0.00	0.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	—	(4)	(7)	(33)	(63)	(58)	(69)	(114)
	EBT margin, %	—	—	—	0.00	0.00	(898.32)	(732.22)	(721.18)	(651.62)	(1,136.25)
	Net income	—	0	—	(4)	(7)	(33)	(63)	(58)	(69)	(114)
	Depreciation	—	—	—	0	0	0	(1)	(6)	(9)	(16)
Per share, $
Per share, $	Revenue	—	—	—	0.00	0.00	0.15	0.21	0.18	0.20	0.16
	Earnings	—	—	—	(5.98)	(7.41)	(1.39)	(1.52)	(1.32)	(1.28)	(1.83)
	Cash flow	—	—	—	(5.72)	(4.77)	(0.72)	(1.03)	(1.15)	(0.82)	(1.33)
	Capex	—	—	—	0.00	0.00	(0.06)	(0.16)	(0.04)	(0.01)	(0.02)
	Free cash flow	—	—	—	(5.72)	(4.77)	(0.78)	(1.19)	(1.19)	(0.82)	(1.34)
	Book value	—	—	—	(5.90)	7.63	15.57	7.73	7.82	19.03	15.44
	Shares, m	—	—	—	1	1	24	41	44	54	62
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	127.65	67.51	60.01	271.80	44.23
	P/B	—	—	—	—	—	1.27	1.81	1.41	2.81	0.89
	EV/Sales	—	—	—	—	—	24.55	29.54	17.45	174.98	(5.76)
	EV/FCF	—	—	—	—	—	(4.84)	(5.15)	(2.69)	(41.94)	1.34
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(4)	(4)	(17)	(43)	(51)	(44)	(82)
	Capex	—	—	—	—	—	(1)	(6)	(2)	0	(1)
	Free cash flow	—	—	—	(4)	(4)	(18)	(49)	(52)	(44)	(83)
Balance, $m
Balance, $m	Working capital	—	—	—	(4)	13	364	316	336	1,016	951
	Total debt	—	—	—	8	22	0	25	—	—	—
	Net debt	—	—	—	(1)	(8)	(375)	(327)	(344)	(1,025)	(967)
	Shareholders’ equity	—	—	—	(4)	7	366	321	344	1,023	957
Returns, %
Returns, %	ROA	—	—	—	(1,179.38)	(80.30)	(16.50)	(16.96)	(15.66)	(9.57)	(11.02)
	ROIC	—	—	—	0.00	0.00	0.00	0.00	(14,209.31)	0.00	0.00
	ROE	—	—	—	35.46	60.08	(18.58)	(18.36)	(17.53)	(10.09)	(11.48)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BCAX Bicara Therapeutics Inc.	$1.2B	— (loss-making)	—	—	n/m	−72.95% (below 0%: shrinking)	—	0.00%	Compare
DMRA Galecto, Inc.	$1.2B	— (loss-making)	—	—	n/m	−877.51% (below 0%: shrinking)	0.00%	0.00%	Compare
VOR Vor Biopharma Inc.	$1.1B	— (loss-making)	—	—	n/m	−47.59% (below 0%: shrinking)	0.00%	—	Compare
NBTX Nanobiotix S.A. - Sponsored ADR	$1.1B	— (loss-making)	—	−71.69% (below 0%: shrinking)	n/m	−177.26% (below 0%: shrinking)	0.00%	0.00%	Compare
REPL Replimune Group, Inc.	$1.1B	— (loss-making)	—	—	n/m	+5.04% (above 0%: growing)	0.00%	0.00%	Compare
IMTX Immatics N.V.	$1.1B	— (loss-making)	— (loss-making)	+97.71% (above 0%: growing)	n/m	−44.41% (below 0%: shrinking)	100.00%	(734.95%)	Compare
JANX Janux Therapeutics, Inc.	$1.1B	— (loss-making)	— (loss-making)	+2,238.72% (above 0%: growing)	n/m	+150.57% (above 0%: growing)	100.00%	(308.66%)
MNKD MannKind Corporation	$1.0B	— (loss-making)	— (loss-making)	+42.92% (above 0%: growing)	n/m	−399.41% (below 0%: shrinking)	72.99%	(0.32%)	Compare
SVRA Savara Inc.	$973.9M	— (loss-making)	— (loss-making)	—	n/m	−14.05% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$1.1B	—	—	+42.92%	—	−60.27%	0.00%	0.00%

All 614 Biotechnology stocks →

Janux Therapeutics, Inc. (JANX) key facts

Concern: Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024.
Concern: Janux Therapeutics, Inc. reported a net loss of $113.6 million, or a loss of $1.83 per share, for fiscal 2025.
Janux Therapeutics, Inc. (JANX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, JANX traded at $16.49, a market capitalization of $1.1 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 43.2× sales.
Return on equity was −11.5% and debt-to-equity 0.00.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is 11.61 (safe zone) for fiscal 2025.